[go: up one dir, main page]

EA202090401A1 - Анти-tim-3 антитела и их применение - Google Patents

Анти-tim-3 антитела и их применение

Info

Publication number
EA202090401A1
EA202090401A1 EA202090401A EA202090401A EA202090401A1 EA 202090401 A1 EA202090401 A1 EA 202090401A1 EA 202090401 A EA202090401 A EA 202090401A EA 202090401 A EA202090401 A EA 202090401A EA 202090401 A1 EA202090401 A1 EA 202090401A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
tim
application
diseases
antigen
Prior art date
Application number
EA202090401A
Other languages
English (en)
Inventor
Минхань Ван
Хой Цзоу
Original Assignee
Фейнз Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фейнз Терапьютикс, Инк. filed Critical Фейнз Терапьютикс, Инк.
Publication of EA202090401A1 publication Critical patent/EA202090401A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны анти-TIM-3 антитела и антигенсвязывающие фрагменты. Также описаны нуклеиновые кислоты, кодирующие эти антитела, композиции, содержащие антитела, и способы получения антител и применения антител для лечения или профилактики заболеваний, таких как рак, воспалительное заболевание, аутоиммунное заболевание, нарушения метаболизма и/или инфекционные заболевания.
EA202090401A 2017-07-28 2018-07-26 Анти-tim-3 антитела и их применение EA202090401A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538277P 2017-07-28 2017-07-28
PCT/US2018/043800 WO2019023410A1 (en) 2017-07-28 2018-07-26 ANTI-TIM-1 ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
EA202090401A1 true EA202090401A1 (ru) 2020-05-18

Family

ID=65040974

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090401A EA202090401A1 (ru) 2017-07-28 2018-07-26 Анти-tim-3 антитела и их применение

Country Status (9)

Country Link
US (1) US11214615B2 (ru)
EP (2) EP3658185A4 (ru)
JP (1) JP2021500916A (ru)
KR (1) KR20200032156A (ru)
CN (1) CN111050797B (ru)
AU (1) AU2018306321A1 (ru)
CA (1) CA3070295A1 (ru)
EA (1) EA202090401A1 (ru)
WO (1) WO2019023410A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021051352A1 (zh) * 2019-09-19 2021-03-25 上药生物治疗（香港）有限公司 一种分离的抗原结合蛋白及其用途
WO2021126538A1 (en) * 2019-12-17 2021-06-24 Phanes Therapeutics, Inc. Bispecific antibodies with alternatively matched interchain cycteines and uses thereof
CN113150150B (zh) * 2020-02-24 2023-08-11 苏州恒康生命科学有限公司 Tim3结合分子及其应用
JP2023525496A (ja) * 2020-04-30 2023-06-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗ｃｄ７９ｂ抗体およびキメラ抗原レセプターならびにそれらの使用方法
CN113151186B (zh) * 2021-02-04 2022-02-18 上海交通大学 抗人cd271的单克隆抗体及用途
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
WO2023105528A1 (en) * 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
WO2025035133A1 (en) * 2023-08-10 2025-02-13 Board Of Regents, The University Of Texas System Bmp-7 antibody compositions & methods for treating cancer
CN119264251B (zh) * 2024-12-09 2025-03-14 上海交通大学医学院附属仁济医院 一种cbln1单克隆抗体和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
EP2216046B1 (en) 2004-07-09 2014-03-12 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
CA2584859C (en) * 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
CA2703947C (en) 2007-10-26 2018-12-04 Governing Council Of The University Of Toronto Therapeutic and diagnostic methods using tim-3
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
HUE040213T2 (hu) * 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-TIM antitest
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8841418B2 (en) * 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CN103173412B (zh) * 2012-12-07 2015-04-22 天津三箭生物技术有限公司 小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
EP3004168A4 (en) * 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN110294807B (zh) 2014-10-27 2023-05-12 新加坡科技研究局 抗tim-3抗体
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN107001475B (zh) 2014-11-06 2021-01-29 豪夫迈·罗氏有限公司 抗tim3抗体及使用方法
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CA2978892A1 (en) 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
SI3277321T1 (sl) 2015-04-01 2024-11-29 Anaptysbio, Inc. Protitelesa, usmerjena proti t-celičnemu imunoglobulinu in mucin protein 3 (tim-3)
CN107847597A (zh) 2015-07-14 2018-03-27 协和发酵麒麟株式会社 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US11014983B2 (en) 2015-08-20 2021-05-25 Sutro Biopharma, Inc. Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
RU2729371C1 (ru) 2015-10-02 2020-08-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические к pd1 и tim3
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease

Also Published As

Publication number Publication date
US11214615B2 (en) 2022-01-04
JP2021500916A (ja) 2021-01-14
CN111050797B (zh) 2024-04-30
CA3070295A1 (en) 2019-01-31
AU2018306321A1 (en) 2020-02-13
EP3658185A4 (en) 2021-07-14
EP4039274A1 (en) 2022-08-10
EP3658185A1 (en) 2020-06-03
CN111050797A (zh) 2020-04-21
KR20200032156A (ko) 2020-03-25
WO2019023410A1 (en) 2019-01-31
US20210032330A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
ZA202000373B (en) Anti-cd47 antibodies and uses thereof
MX2024015440A (es) Anticuerpos anti-phf-tau y usos de estos
HK1255604A1 (zh) 抗pd-l1抗体及其用途
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
HK1254880A1 (zh) 抗pd-1抗體及其應用
HK1255331A1 (zh) 抗pcsk9抗體及其應用
PH12017501522A1 (en) Antibodies to tau and uses thereof
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202190807A1 (ru) Антитела к синуклеину
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение
EA201990493A1 (ru) Антитела к гм-ксф и их применения
EA202092121A1 (ru) Антитела против cd73 и их применения
EA202090603A1 (ru) Анти-lag-3 антитела и их применение
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
EA202092947A1 (ru) Анти-pvrig/анти-tigit биспецифические антитела и способы их применения